Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant

• Published in: bioRxiv 2021-06
• Main Authors: Thorne, Lucy G, Bouhaddou, Mehdi, Ann-Kathrin Reuschl, Zuliani-Alvarez, Lorena, Polacco, Benjamin J, Pelin, Adrian, Batra, Jyoti, Whelan, Matthew Vx, Ummadi, Manisha, Roic, Ajda, Turner, Jane, Obernier, Kirsten, Braberg, Hannes, Soucheray, Margaret, Richards, Alicia L, Kuei-Ho, Chen, Harjai, Bhavya, Memon, Danish, Hosmillo, Myra, Hiatt, Joseph, Jahun, Aminu S, Goodfellow, Ian G, Noursadeghi, Mahdad, Fabius, Jacqueline, Shokat, Kevan, Jura, Natalia, Verba, Kliment A, Beltrao, Pedro, Swaney, Danielle L, Garcia-Sastre, Adolfo, Jolly, Clare, Towers, Greg J, Krogan, Nevan J
• Format: Article
• Language: English
• Subjects: Adaptation; Antagonism; Antagonists; Antiviral agents; Biotechnology; Epithelial cells; Immune evasion; Immune response; Innate immunity; Laboratories; Mitochondria; mRNA; Patent applications; Phosphorylation; Protein biosynthesis; Proteins; Proteomics; Replication; Severe acute respiratory syndrome coronavirus 2; Transcription
• DOI: 10.1101/2021.06.06.446826

Emergence of SARS-CoV-2 variants, including the globally successful B.1.1.7 lineage, suggests viral adaptations to host selective pressures resulting in more efficient transmission. Although much effort has focused on Spike adaptation for viral entry and adaptive immune escape, B.1.1.7 mutations outside Spike likely contribute to enhance transmission. Here we used unbiased abundance proteomics, phosphoproteomics, mRNA sequencing and viral replication assays to show that B.1.1.7 isolates more effectively suppress host innate immune responses in airway epithelial cells. We found that B.1.1.7 isolates have dramatically increased subgenomic RNA and protein levels of Orf9b and Orf6, both known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein required for RNA sensing adaptor MAVS activation, and Orf9b binding and activity was regulated via phosphorylation. We conclude that B.1.1.7 has evolved beyond the Spike coding region to more effectively antagonise host innate immune responses through upregulation of specific subgenomic RNA synthesis and increased protein expression of key innate immune antagonists. We propose that more effective innate immune antagonism increases the likelihood of successful B.1.1.7 transmission, and may increase in vivo replication and duration of infection. Competing Interest Statement The Krogan Laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. Nevan Krogan has consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Maze Therapeutics and Interline Therapeutics, is a shareholder of Tenaya Therapeutics and has received stocks from Maze Therapeutics and Interline Therapeutics. The A.G.-S. laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix and Merck. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak and Pfizer. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections, owned by the Icahn School of Medicine at Mount Sinai, New York.